SCHEMBL2535698

SCHEMBL2535698

N#Cc1cc(-c2nc3cncnc3s2)ccc1Oc1ccc(F)cc1

nearest known ligand 0.44

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 11/20 0.44
HPGD P15428 4/20 0.41
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 3/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
SCN9A Q15858 3/20 0.40
APP P05067 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
AHR P35869 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4141873 0.90 ALDH1A1 (0.38) SLC22A12HPGDALDH1A1KDM4EMEN1
SCHEMBL4159263 0.90 SLC22A12 (0.41) SLC22A12HPGDALDH1A1KDM4EMEN1
SCHEMBL2532037 0.90 ALDH1A1 (0.41) HPGDALDH1A1KDM4EMEN1KMT2A
SCHEMBL4146990 0.89 SLC22A12 (0.46) SLC22A12HPGDALDH1A1SCN9ANPSR1
SCHEMBL4146427 0.89 ALDH1A1 (0.37) SLC22A12HPGDALDH1A1KDM4EMEN1
Potassium SCHEMBL4146433 0.89 ALDH1A1 (0.37) SLC22A12HPGDALDH1A1KDM4EMEN1
SCHEMBL4300552 0.87 ALDH1A1 (0.36) SLC22A12HPGDALDH1A1KDM4ESCN9A
SCHEMBL4151888 0.87 SLC22A12 (0.44) SLC22A12SCN9A
SCHEMBL4152592 0.85 ALDH1A1 (0.52) SLC22A12HPGDALDH1A1NPSR1
Hydrochloric Acid SCHEMBL4163294 0.84 ALDH1A1 (0.51) SLC22A12HPGDALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3263109-B1 DRUG FOR PREVENTING AND/OR TREATING DEMENTIA NAT UNIV CORP TOTTORI UNIV (JP) 2020-06-17 EP claimed
EP-3219319-A1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT Nippon Chemiphar Co., Ltd. (JP) 2017-09-20 EP claimed
EP-2036561-B1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT NIPPON CHEMIPHAR CO (JP) 2017-05-10 EP claimed
US-20110257201-A1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT NIPPON CHEMIPHAR CO., LTD. (JP) 2011-10-20 US claimed
US-20100234399-A1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT NIPPON CHEMIPHAR CO., LTD. (JP) 2010-09-16 US claimed
EP-2036561-A1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT Nippon Chemiphar Co., Ltd. (JP) 2009-03-18 EP claimed
EP-3263109-B1 DRUG FOR PREVENTING AND/OR TREATING DEMENTIA NAT UNIV CORP TOTTORI UNIV (JP) 2020-06-17 EP disclosed
US-10413546-B2 Drug for preventing and/or treating dementia NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY (JP) 2019-09-17 US disclosed
US-20180117047-A1 DRUG FOR PREVENTING AND/OR TREATING DEMENTIA NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY (JP) 2018-05-03 US disclosed
EP-3263109-A1 DRUG FOR PREVENTING AND/OR TREATING DEMENTIA National University Corporation Tottori University (JP) 2018-01-03 EP disclosed
EP-3219319-A1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT Nippon Chemiphar Co., Ltd. (JP) 2017-09-20 EP disclosed
EP-3219319-A1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT Nippon Chemiphar Co., Ltd. (JP) 2017-09-20 EP disclosed
EP-2036561-B1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT NIPPON CHEMIPHAR CO (JP) 2017-05-10 EP disclosed
US-20100234399-A1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT NIPPON CHEMIPHAR CO., LTD. (JP) 2010-09-16 US disclosed
CN-101505755-A Agent for overcoming resistance to anticancer drug NIPPON CHEMIPHAR CO (JP) 2009-08-12 CN disclosed
US-20090149452-A1 XANTHINE OXIDASE INHIBITOR NIPPON CHEMIPHAR CO., LTD. (JP) 2009-06-11 US disclosed
EP-2036561-A1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT Nippon Chemiphar Co., Ltd. (JP) 2009-03-18 EP disclosed
EP-2036561-A1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT Nippon Chemiphar Co., Ltd. (JP) 2009-03-18 EP disclosed
EP-1911760-A1 XANTHINE OXIDASE INHIBITOR Nippon Chemiphar Co., Ltd. (JP) 2008-04-16 EP disclosed
WO-2007148835-A1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT NIPPON CHEMIPHAR CO., LTD. (JP) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180117047-A1 DRUG FOR PREVENTING AND/OR TREATING DEMENTIA XDH, ACHE, DDO SLC22A12 1046/4885HPGD 34/4885ALDH1A1 455/4885
US-20090149452-A1 XANTHINE OXIDASE INHIBITOR XDH, PNPO, CBR1 SLC22A12 1556/4885HPGD 143/4885ALDH1A1 304/4885
US-10413546-B2 Drug for preventing and/or treating dementia XDH, ACHE, DDO SLC22A12 1046/4885HPGD 34/4885ALDH1A1 455/4885
US-20100234399-A1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT TMX1, TPX2, XDH SLC22A12 1317/4885HPGD 386/4885ALDH1A1 1351/4885
US-20110257201-A1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT TMX1, TPX2, XDH SLC22A12 1317/4885HPGD 386/4885ALDH1A1 1351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.